Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-α

Brain, Behavior, and Immunity

Volumn 18, Issue 6, 2004, Pages 555-562

  Schaefer, Martin ^a   Horn, Martin ^b   Schmidt, Folkhard ^b   Schmid Wendtner, Monika H ^c   Volkenandt, Matthias ^c   Ackenheil, Manfred ^b   Mueller, Norbert ^b   Schwarz, Markus J ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Blood brain barrier; Cytokines; Depression; Interferon ; Melanoma; sICAM 1

Indexed keywords

ALPHA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM;

ADJUVANTS, IMMUNOLOGIC; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; DEPRESSIVE DISORDER; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SKIN NEOPLASMS;

EID: 4344703375     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2004.02.002     Document Type: Article

References (52)

1. Baraczka K., Nekam K., Pozsonyi T., Jakab L., Szongoth M., Sesztak M. Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1 and sL-selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement. Neuroimmunomodulation. 9:2001;49-54
2. Black P.H., Garbutt L.D. Stress, inflammation and cardiovascular disease. J. Psychosom. Res. 52:2002;1-23
3. Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., Almerighi C., Verkerk R., Meltzer H., Maes M. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J. Clin. Psychopharmacol. 22:2002;86-90
4. Bonaccorso S., Puzella A., Marino V., Pasquini M., Biondi M., Artini M., Almerighi C., Levrero M., Egyed B., Bosmans E., Meltzer H.Y., Maes M. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 105:2001;45-55
5. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatry. 160:2003;1342-1345
6. Cassidy E.M., Manning D., Byrne S., Bolger E., Murray F., Sharifi N., Wallace E., Keogan M., O'Keane V. Acute effects of low-dose interferon-alpha on serum cortisol and plasma interleukin-6. J. Psychopharmacol. 16:2002;230-234
7. Del Maschio A., De Luigi A., Martin-Padura I., Brockhaus M., Bartfai T., Fruscelaa P., Adorini L., Martino G., Furlan R., De Simoni M.G., Dejana E. Leukocyte recruitment in the cerebrospinal fluid of mice with experimental meningitis is inhibited by an antibody to junctional adhesion molecule (JAM). J. Exp. Med. 190:1999;1351-1356
8. Derogatis L.R., Morrow G.R., Fetting J., Penman D., Piasetsky S., Schmale A.M., Henrichs M., Carnicke L. Jr. The prevalence of psychiatric disorders among cancer patients. JAMA. 249:1983;751-757
9. Dieperink E., Willenbring M., Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am. J. Psychiatry. 157:2000;867-876
10. Dietrich J.B. The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier. J. Neuroimmunol. 128:2002;58-68
11. Elenkov I.J., Chrousos G.P. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann. N. Y. Acad. Sci. 966:2002;290-303
12. Engelhardt B., Conley F.K., Butcher E.C. Cell adhesion molecules on vessels during inflammation in the mouse central nervous system. J. Neuroimmunol. 51:1994;199-208
13. Frei K., Piani D., Pfister H.W., Fontana A. Immune-mediated injury in bacterial meningitis. Int. Rev. Exp. Pathol. 34(Pt. B):1993;183-192
14. Hakansson A., Gustafsson B., Krysander L., Hjelmqvist B., Rettrup B., Hakansson L. Expression of ICAM-1 during IFN-alpha-based treatment of metastatic malignant melanoma: relation to tumor-infiltrating mononuclear cells and regressive tumor changes. J. Interferon Cytok. Res. 19:1999;171-177
15. Hancock B.W., Harris S., Wheatley K., Gore M. Adjuvant interferon-alpha in malignant melanoma: current status. Cancer Treat. Rev. 26:2000;81-89
16. Heinz A., Hermann D., Smolka M.N., Rieks M., Graf K.J., Pohlau D., Kuhn W., Bauer M. Effects of acute psychological stress on adhesion molecules, interleukins and sex hormones: implications for coronary heart disease. Psychopharmacology (Berl.). 165:2003;111-117
17. Hickey W.F. Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol. 1:1991;97-105
18. Hurlock E.C. Interferons: potential roles in affect. Med. Hypotheses. 56:2001;558-566
19. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern cooperative oncology group trial EST 1684. J. Clin. Oncol. 14:1996;7-17
20. Kirkwood J.M., Richards T., Zarour H.M., Sosman J., Ernstoff M., Whiteside T.L., Ibrahim J., Blum R., Wieand S., Mascari R. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 95:2002;1101-1112
21. Kraus J., Oschmann P., Engelhardt B., Schiel C., Hornig C., Bauer R., Kern A., Traupe H., Dorndorf W. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta. Neurol. Scand. 98:1998;102-109
22. Krieglstein C.F., Granger D.N. Adhesion molecules and their role in vascular disease. Am. J. Hypertens. 14:2001;44S-54S
23. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry. 157:2000;683-694
24. Lansky S.B., List M.A., Herrmann C.A., Ets-Hokin E.G., DasGupta T.K., Wilbanks G.D., Hendrickson F.R. Absence of major depressive disorder in female cancer patients. J. Clin.Oncol. 3:1985;1553-1560
25. Lee S.J., Benveniste E.N. Adhesion molecule expression and regulation on cells of the central nervous system. J. Neuroimmunol. 98:1999;77-88
26. Lespérance F., Frasure-Smith N., Théroux P., Irwin M. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am. J. Psychiatry. 161:2004;271-277
27. Licinio J., Kling M.A., Hauser P. Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin. Oncol. 25:1998;30-38
28. Maes M., Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., Almerighi C., Meltzer H. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol. Psychiatry. 6:2001;475-480
29. Maes M., De Ruyter M., Claes R., Suy E. Self rated depression in relation to DSM-III classification: a statistical isolinear multiple components analysis. Acta. Psychiatr. Scand. 77:1988;27-31
30. McDaniel J.S., Musselman D.L., Porter M.R., Reed D.A., Nemeroff C.B. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch. Gen. Psychiatry. 52:1995;89-99
31. Millman R.P., Fogel B.S., McNamara M.E., Carlisle C.C. Depression as a manifestation of obstructive sleep apnea: reversal with nasal continuous positive airway pressure. J. Clin. Psychiatry. 50:1989;348-351
32. Oehmichen M., Domasch D., Wietholter H. Origin, proliferation, and fate of cerebrospinal fluid cells. A review on cerebrospinal fluid cell kinetics. J. Neurol. 227:1982;145-150
33. Pan W., Banks W.A., Kastin A.J. Permeability of the blood-brain and blood-spinal cord barriers to interferons. J. Neuroimmunol. 76:1997;105-111
34. Pehamberger H., Soyer H.P., Steiner A., Kofler R., Binder M., Mischer P., Pachinger W., Aubock J., Fritsch P., Kerl H., Wolff K. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian malignant melanoma cooperative group. J. Clin. Oncol. 16:1998;1425-1429
35. Plotkin S.R., Banks W.A., Kastin A.J. Comparison of saturable transport and extracellular pathways in the passage of interleukin-1 alpha across the blood-brain barrier. J. Neuroimmunol. 67:1996;41-47
36. Preston R.A., Ledford M., Materson B.J., Baltodano N.M., Memon A., Alonso A. Effects of severe, uncontrolled hypertension on endothelial activation: soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1 and von Willebrand factor. J. Hypertens. 20:2002;871-877
37. Rieckmann P., Nunke K., Burchhardt M., Albrecht M., Wiltfang J., Ulrich M., Felgenhauer K. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J. Neuroimmunol. 47:1993;133-140
38. Rieckmann P., Michel U., Albrecht M., Bruck W., Wockel L., Felgenhauer K. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J. Neuroimmunol. 60:1995;9-15
39. Rieckmann P., Altenhofen B., Riegel A., Baudewig J., Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann. Neurol. 41:1997;326-333
40. Risau W., Esser S., Engelhardt B. Differentiation of blood-brain barrier endothelial cells. Pathol. Biol. (Paris). 46:1998;171-175
41. Schaefer M., Engelbrecht M.A., Gut O., Fiebich B.L., Bauer J., Schmidt F., Grunze H., Lieb K. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog. Neuropsychopharmacol. Biol. Psychiatry. 26:2002;731-746
42. Schwarz M.J., Ackenheil M., Riedel M., Müller N. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci. Lett. 253:1998;201-203
43. Schwarz M.J., Riedel M., Ackenheil M., Müller N. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry. 47:2000;29-33
44. Swiatkowski M., Rybakowski J.K. Depression and T lymphocytes in patients with irritable bowel syndrome. J. Affect. Disord. 28:1993;199-202
45. Taylor J.L., Grossberg S.E. The effects of interferon-alpha on the production and action of other cytokines. Semin. Oncol. 25:1998;23-29
46. Thomas A.J., Ferrier I.N., Kalaria R.N., Woodward S.A., Ballard C., Oakley A., Perry R.H., O'Brien J.T. Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. Am. J. Psychiatry. 157:2000;1682-1684
47. Valentine A.D., Meyers C.A., Kling M.A., Richelson E., Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin. Oncol. 25:1998;39-47
48. van de Stolpe A., van der Saag P.T. Intercellular adhesion molecule-1. J. Mol. Med. 74:1996;13-33
49. van West D., Maes M. Activation of the inflammatory response system: a new look at the etiopathogenesis of major depression. Neuroendocrinol. Lett. 20:1999;11-17
50. Weller R.O., Engelhardt B., Phillips M.J. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol. 6:1996;275-288
51. Wiranowska M., Wilson T.C., Thompson K., Prockop L.D. Cerebral interferon entry in mice after osmotic alteration of blood-brain barrier. J. Interferon Res. 9:1989;353-362
52. Zung W.W., Richards C.B., Short M.J. Self-rating depression scale in an outpatient clinic. Further validation of the SDS. Arch. Gen. Psychiatry. 13:1965;508-515